Front Line Genomics

Have you got questions about #singlecell or #spatialomics? The latest report from Front Line Genomics is our most comprehensive yet, pulling together the latest research and the intelligence of experts in the field. The report has dedicated chapters to cover each of the major areas of technological development: 🔬 Chapter 1 – Cell Prep Possibilities : Sample Prep and Cell Isolation Methods for Single-cell 🔬 Chapter 2 – Single-Cell Solutions: Methods, Kits & Instruments for Single-Cell 🔬 Chapter 3 – Spatial Selection: Comparing Spatial Transcriptomic Workflows 🔬 Chapter 4 – Proteomic Predicament: Finding the Right Spatial Proteomic Approach 🔬 Chapter 5 - Finding Focus: Sample Prep, Imaging and Microscopy for Spatial Biology 🔬 Chapter 6 - In Addition: Incorporating Multi-Omics in Single-cell and Spatial Workflows 🔬 Chapter 7 – Outsourcing Outlook: The Benefits of Outsourcing Single-Cell and Spatial 🔬 Chapter 8 - Analysis Aid: Ways to get the most out of your Single-Cell and Spatial Data 🔬 Chapter 9 - Broader Considerations: ESG, Lawsuits and the Wild West It also has interviews, quotes and comments from 19 single-cell and spatial experts, discussing their preferences for instruments and their advice for different kits. One feature of particular value are the three expert interludes that are published between the chapters of this report. In these interludes, three or four single-cell and spatial scientists sit on a panel and answer Q&A style questions from a live audience on their specific challenges working with these technologies. This has been turned into a transcript for you to enjoy and learn from. You can scroll through below to see an example of this content. A big thanks to the panel members for helping put this together! - Linda Orzolek, Mandovi Chatterjee, Josh Fienman, Devjanee Swain Lenz, Cátia Moutinho, Andrea Corsinotti, Jan-Philipp Mallm, Jonathan Coxhead & Samuel Jackson The whole report is free to download, just like all of our reports. They are designed to promote better understanding across the community and help move this field forward. If you are interested in reading this report, you can fill in this form and a copy of the report will be emailed to you -> https://hubs.ly/Q02xXNx40 #spatialbiology #singlecellsequencing

How do we get out of the ‘scientific wild west’ that has emerged in the fields of #singlecell and #spatialomics? 🤠 There's one simple answer – Community. By coming together and sharing knowledge, we can better understand the state of play and make better decisions. The Single-cell & Spatial Buyer’s Guide is our offering to help people with their decision making in single-cell and spatial omics. Within this intelligence report, there are direct comparisons of existing technologies for all the steps of a standard single-cell and spatial workflow. That means comparisons of the specs and the most suitable applications for the available tools. It is also filled with interviews from experts who are working with these technologies and ready to share their experiences with you. That includes transcripts from single-cell and spatial roundtables and 1:1 interviews from individuals who have worked with these technologies. Check out some of our favourite insights featured in the report below. If you are interested in reading this report, you can fill in this form and a copy of the report will be emailed to you for free -> https://hubs.ly/Q02xXNx40

Got five minutes to catch up on the latest news from the genomics world and beyond? Week in Brief has everything you need! Top stories this week include: 🧬In a bid to understand the potential of AI in healthcare settings, researchers have discovered that some tools can make accurate diagnoses from textbook-like descriptions of illness, but are less effective when presented with a summary generated by the patient themselves. 🧬A study using genomic data from several international sources has revealed new, rare genetic variants that are linked to the onset of Parkinson’s disease. 🧬New recommendations have been published regarding the reporting of next generation sequencing data. The guidelines aim to help clinicians make better decisions for treatment and diagnosis. Check out the full article on the Front Line Genomics website: https://lnkd.in/eemJYATZ

“Greater than 70% of cancer deaths right now occur in tumour types without an established screening programme.” Liquid biopsy is poised to redefine the way we approach diagnostics and personalized medicine in the treatment of complex diseases. In the last year, we have seen some incredible developments within the field, further illustrating the clinical utility of this transformative technique. However, the field is rapidly progressing, making it difficult to keep track of the latest assays, research and trial results. To address this issue, we released the Liquid Biopsy Intelligence Report this year, a free-to-download resource bringing you the advancements, insights and research from leading experts in the liquid biopsy field. This report covers the most impactful developments in liquid biopsy from the last year. Containing 7 in-depth chapters exploring areas covering major liquid biopsy clinical trials, developments in multi-cancer detection tests, biomarker discovery and the role of liquid biopsy in neurological disorders, this report features the latest and most exciting findings this year had to offer. We’ve included a little insight into this free report, an interview with Professor Charles Swanton and the NHS-Galleri Trial. Read below to hear how the trial has been designed and what the future might hold in the coming years. To get the full report, follow this link https://hubs.la/Q02ktKtF0 #liquidbiopsy #cancerresearch #biomarkers

Looking for the latest genomics news? You’re in the right place! Check out some snippets from the latest Week in Brief below. 🧬A new antibiotic class, which works by targeting two key bacterial mechanisms, could be immune to the effects of antibiotic resistance. This is because it is highly unlikely that the microbes would acquire mutations that impact both modes of action. 🧬Researchers have published the most extensive single-cell atlas of the human kidney to date, using both healthy and diseased cells. 🧬Women who have been diagnosed with, and treated for, hereditary forms of ovarian cancer are subsequently at a lower risk for breast cancer, according to a new study. Read the full article on our website: https://lnkd.in/e3-NBQtF

Liquid biopsies are being heralded as “the future of non-invasive cancer diagnosis and treatment”. But what’s stopping their clinical implementation? Find out the answer to this, and more, as we dive into the latest research, trials and advances pushing the field forwards in our free Liquid Biopsy 2024 Report. This report includes: 💉 A helpful guide to liquid biopsy biomarker analysis, including the latest products, equipment and commercially available assays. 💉 Exclusive interviews and insights from 17 expert contributors within the field, including Klaus Pantel, Lauren Leiman and Charles Swanton. 💉 Exciting updates and results from major clinical trials and programmes, including the eagerly awaited NHS-Galleri trial. 💉 A comprehensive overview of the applications of liquid biopsy, including early cancer detection, MRD analysis and the diagnosis of neurological disorders. 💉 Insights into how liquid biopsy is currently changing oncological care within the NHS and beyond, and a glimpse into the future of this transformative technique. We’ve gathered expert intelligence from these leaders within the liquid biopsy field, below we have provided a sneak peak of an interview with Aadel Chaudhuri, MD PhD How do we figure out which patients will benefit from cancer therapies? Answering this question, Dr. Chaudhuri and colleagues are adopting liquid biopsy approaches to risk stratify oligometastatic NSCLC patients before radiotherapy treatment. In this interview, we speak with Aadel to uncover the details of his ctDNA study and its implications on the future of liquid biopsy for NSCLC patients. To get the full report, follow this link https://hubs.la/Q02ktKtF0 #liquidbiopsy #cancerresearch #biomarkers

Are you curious about what's been going on in the genomics world - and beyond - in the last seven days? Here's a sneak peek of what you can find in today's Week in Brief. 🧬Llama-derived nanobodies have shown potential for the treatment of HIV, with the results of a recent study showing that these molecules can effectively target and neutralise HIV-1 strains. 🧬Researchers have developed a new method of non-invasive prenatal genetic testing to identify maternal copy number variants associated with Duchenne muscular dystrophy. 🧬According to a new study, around 2% of the population develops autoantibodies against type 1 interferons – a key component of the immune system – during their life. This leaves these individuals more susceptible to viral infection. Check out the full article here: https://lnkd.in/eTvZDSew

🩸 Have You Read The Liquid Biopsy 2024 Intelligence Report? 🩸 It’s the quickest way to find the latest clinical advancements, scientific breakthroughs and cutting-edge assays It contains 7 in-depth chapters exploring areas ranging from novel biomarkers to major liquid biopsy clinical trials, to the current state and future applications of this revolutionary technology in oncological and neurological care. Designed to be a free resource for the liquid biopsy community, this report features the latest and most exciting findings this last year had to offer. Best of all, this resource is FREE to download from our website: https://hubs.la/Q02ktKtF0 This resource was built with the help of contributors from across the liquid biopsy community. Below we have included a highlight from Mike Hubank, who kindly took part in an interview with Ashleigh Davey about the Marsden360 assay. Click through below to read the full interview. The report contains much more along the same lines! We hope you find this report a useful and interesting window into the rapidly developing world of liquid biopsy! #liquidbiopsy #cancer #cancerresearch

In just a few hours, we’ll be hearing from Dr. Rolph Pfundt and Dr. Swati Tomar in the new 'Enhancing Variant Interpretation' Webinar! Click more to see what will be covered 🤔 Using the experiences of Rolph and Swati, alongside case studies (including disease-associated variants in Charcot-Marie-Tooth and Breast Cancer), this webinar will show: 💫 How to resolve splice-site variants using scores and predictors in a visual interface. 💫 Ways to conduct familial variant analysis to prioritize germline variants 💫 Best practices for using trusted databases, predictors, publications and guidelines (including ACMG criteria) 💫 The significance of a guideline-driven approach to variant nomenclature 💫 A variant interpretation software that offers comprehensive annotations and visualization of breakpoints, and coverage across different file types in a full genome browser. The webinar starts at 3pm (BST) and will feature plenty of time for Q&A and interaction with the speakers 💬 🗨 To register, please click the link here: https://hubs.la/Q02F_lTn0 #genomics #mutation #variant

𝐖𝐞𝐛𝐢𝐧𝐚𝐫 𝟐: 𝐄𝐧𝐡𝐚𝐧𝐜𝐢𝐧𝐠 𝐘𝐨𝐮𝐫 𝐌𝐮𝐥𝐭𝐢-𝐎𝐦𝐢𝐜 𝐖𝐨𝐫𝐤𝐟𝐥𝐨𝐰𝐬 𝐰𝐢𝐭𝐡 𝐃𝐚𝐭𝐚 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧 𝘛𝘶𝘦𝘴𝘥𝘢𝘺 16𝘵𝘩 𝘑𝘶𝘭𝘺 2024 𝘢𝘵 3𝘱𝘮 𝘉𝘚𝘛 / 4𝘱𝘮 𝘊𝘌𝘛/ 10𝘢𝘮 𝘌𝘋𝘛 Webinar 2 will look at some unique examples of multi-omic integration, including reactome, cytoprofiling, and pathway-based multi-omics. These methods allow you to integrate multi-omics data in ways that can have a stronger impact in research and translational settings. Speakers: 🔸 Eliot Ragueneau, Senior Software Engineer, EMBL-EBI Eliot will begin with a short introduction to Reactome, followed by a brief explanation of the principles behind the different analysis methods. There will also be a demo of Reactome GSA in a multi-comics context. 🔸 Abbey Cutchin, Associate Director, Strategic Marketing, Element Biosciences Abbey will take us through how Element can support your research with their flexible, upgradable systems all with uncompromising performance and affordability. Take this opportunity to Shift Your Science with the full potential of AVITI24 CytoProfiling. 🔸 Cecilia Wieder, Research Associate, Imperial College London Cecilia will introduce the PathIntegrate package and showcase its use on COPD and COVID-19 multi-omics data (transcriptomics, proteomics, and metabolomics) 🔸 Stathis Megas, Post-Doc Fellow, Wellcome Sanger Institute This talk will present a new method, EmptyDropsMultiome for discriminating real cells from background, which will be shown to outperform CellRanger ARC on real datasets You can register for this webinar by following this link: https://hubs.la/Q02FlHr90